H-YLEPGPVTV^-OH

Ref. 3D-PP47413

Produktinformation

• Name: H-YLEPGPVTV^-OH

Beschreibung

Peptide H-YLEPGPVTV^-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-YLEPGPVTV^-OH include the following: Identification of the risk HLA-A alleles and autoantigen in Han Chinese vitiligo patients and the association of CD8+ T cell reactivity with disease X Yi, T Cui, S Li, Y Yang, J Chen, S Guo - Medical Journal of , 2018 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154310/ and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide WJ Lesterhuis , G Schreibelt, NM Scharenborg - Cancer immunology , 2011 - Springerhttps://link.springer.com/article/10.1007/s00262-010-0942-x HLA class I-redirected anti-tumour CD4+ T-cells require a higher TCR binding affinity for MP Tan, GM Dolton , AB Gerry, JE Brewer - Nat Rev , 2013 - cyberleninka.orghttps://cyberleninka.org/article/n/647948.pdf Human leucocyte antigen class I-redirected anti-tumour CD4+ T cells require a higher T cell receptor binding affinity for optimal activity than CD8+ T cells MP Tan, GM Dolton , AB Gerry, JE Brewer - Clinical & , 2017 - academic.oup.comhttps://academic.oup.com/cei/article-abstract/187/1/124/6412049 Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides ML Salgaller, FM Marincola, JN Cormier - Cancer research, 1996 - AACRhttps://aacrjournals.org/cancerres/article-abstract/56/20/4749/502744 HLA class I-redirected anti-tumour CD4+ T-cells require a higher TCR binding affinity for optimal activity than CD8+ T-cells M Tan, GM Dolton , AB Gerry, JE Brewer - Clinical and , 2017 - orca.cardiff.ac.ukhttps://orca.cardiff.ac.uk/id/eprint/93910/ Unconventional modes of peptide-HLA-I presentation change the rules of TCR engagement JR Hopkins, BJ MacLachlan , S Harper - Discovery , 2022 - academic.oup.comhttps://academic.oup.com/discovimmunology/article-abstract/1/1/kyac001/6580421 of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene H Zarour, C De Smet , F Lehmann, M Marchand - Journal of investigative , 1996 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0022202X15426260 Immunization Using Autologous Dendritic Cells Pulsed with the Melanoma-Associated Antigen gp100-Derived G280-9V Peptide Elicits CD8+ Immunity GP Linette, D Zhang, FS Hodi, EP Jonasch - Clinical cancer , 2005 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/11/21/7692/194189 Recombinant human single-chain MHC-peptide complexes made from E. coli by in vitro refolding: functional single-chain MHC-peptide complexes and tetramers G Denkberg, CJ Cohen , D Segal - European journal of , 2000 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/1521-4141(2000012)30:12%3C3522::AID-IMMU3522%3E3.0.CO;2-D Using X-ray crystallography, biophysics, and functional assays to determine the mechanisms governing T-cell receptor recognition of cancer antigens BJ MacLachlan , A Greenshields-Watson - JoVE (Journal of , 2017 - jove.comhttps://www.jove.com/t/54991/using-x-ray-crystallography-biophysics-functional-assays-to-determine Recruitment of CTL activity by tumor-specific antibody-mediated targeting of single-chain class I MHC-peptide complexes A Lev, H Novak, D Segal, Y Reiter - The Journal of Immunology, 2002 - journals.aai.orghttps://journals.aai.org/jimmunol/article/169/6/2988/35346

• Marke: Biosynth